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The ability of staurosporine, a potent inhibitor of protein kinase C, to block certain cellular events initiated by 12-0- 
tetradecanoylphorbol-13-acetate (TPA) and epidermal growth factor (EGF) was examined. Treatment of MDA468 
breast cancer cells with TPA decreases EGF binding to the cell surface and this effect is blocked by pretreatment with 
staurosporine with an ICs0 of 30 nM. Either 10 -9 M EGF or 100 ng/ml TPA stimulated the accumulation f both EGF 
receptor and TGF-a mRNA and staurosporine (50 nM) completely abolished these mRNA accumulations. Staurosporine 
did not block EGF-stimulated tyrosine phosphorylation f its receptor as measured by immunoblotting with anti-phos- 
photyrosine antibodies. The ability of staurosporine to block the mRNA responses of either EGF or TPA suggests that 
these two agents have common signaling pathways and it implies a role for protein kinase C in the control f EGF recep- 
tor and TGF-~t expression. 
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I. INTRODUCTION 
Protein kinase C is a CaZ+/phospholipid - 
dependent enzyme that is activated irectly by 
diacylglycerol generated during receptor-mediated 
inositol phospholipid turnover [1,2] or by tumor 
promoters uch as 12-O-tetradecanoylphorbol-13- 
acetate (TPA) [3-5]. Activation of protein kinase 
C is known to have a variety of effects on cells (for 
review, see [6]) and is thought o play important 
roles in both signal transduction and cellular pro- 
liferation. In MDA468 cells, we have utilized TPA 
to examine the effects of protein kinase C activa- 
tion on epidermal growth factor (EGF) receptor 
and transforming growth factor-or (TGF-c0 expres- 
sion and have found that TPA stimulates the ac- 
cumulation of both EGF receptor and TGF-ce 
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mRNA. We have also shown that EGF can stimu- 
late EGF receptor and TGF-a mRNA accumula- 
tion and have previously postulated that protein 
kinase C may have an important role in these ac- 
tions of EGF [7]. To further characterize the role 
of protein kinase C in EGF action, we have 
employed the recently described protein kinase C 
antagonist, staurosporine [8], and have found that 
it blocks the stimulation of EGF receptor and 
TGF-a expression i duced by both TPA and EGF. 
This finding is compatible with our earlier hypo- 
thesis that the protein kinase C is a key enzyme in 
mediating the effects of TPA and EGF on EGF 
receptor and TGF-a expression in the MDA468 
human breast cancer cell line. 
2. MATERIALS AND METHODS 
2.1. Materials 
Staurosporine (from Kyowa Hakko Kogyo, Japan) was 
dissolved in dimethyl sulfoxide. Mouse monoclonal antibody 
B1D8 against he EGF receptor was prepared as in [9]. Rabbit 
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anti-phosphotyrosine a tibodies were prepared and purified as 
described by Kamps and Sefton [10]. 
2.2. Cell cultures 
MDA468 cells were maintained in a CO2 incubator on 15-cm 
Falcon tissue culture plates in Dulbecco's modified Eagle's 
medium containing 10070 calf serum plus penicillin and gen- 
tamicin. 
2.3. EGF-binding studies 
EGF binding was quantitated asdescribed [7] using ~25I-EGF 
equivalent to 8 × 10 -ll M EGF (30000 cpm/well). 
2.4. RATA preparation and hybridization 
RNA was prepared by the method of Chirgwin et al. [111. 
20/zg total RNA per lane was electrophoresed in 1 aT0 agarose, 
2.2 M formaldehyde g ls [12]. The RNA was transferred to 
nitrocellulose, prehybridized, and hybridized with the ap- 
propriate [32P]cDNA probe (EGF receptor [13]; TGF-a [14]) 
labeled [15] to a specific activity of 2.0 x 109 dpm//~g. Un- 
bound probe was washed off at high stringency [16]. 
2.5. Elution of hybridized probes 
The blot was washed in 500 ml of 2 mM Tris, 2 mM EDTA, 
0.1070 SDS (pH 8.2) for 20 rain at 65°C [17]. 
2.6. Measurement of phosphotyrosine incorporation into the 
EGF receptor 
The MDA468 cells were rinsed twice with ice-cold PBS, and 
lysed with 2.0 ml ice-cold phosphate-RIPA buffer containing 
2 mM EDTA and 1 mM sodium orthovanadate as described by 
Kamps and Sefton [10]. The samples were thoroughly mixed by 
vortex-mixing and spun at 13000 × g for 15 min at 4oC to 
remove insoluble material. 200/A of the supernatant was 
removed and 20/~g of the anti-EGF receptor monoclonal an- 
tibody B1D8 was added. After incubation for 2 h at 4°C, 100/A 
fixed S. aureus (Pansorbin, Calbiochem) was added and in- 
cubated for 30 min. The bacterial complex was then centrifuged 
and washed twice with the cell-lysing buffer, resuspended and 
boiled in Laemmli sample buffer, and the supernatant elec- 
trophoresed on a 7.5070 SDS-polyacrylamide gel[18]. The pro- 
tein in the gel was then electrophoretically transferred to 
nitrocellulose [10] followed by incubation of the blot overnight 
at 4°C in blocking buffer [10]. The blot was incubated inblock- 
ing buffer containing 0.75/~g/ml affinity*purified phospho- 
tyrosine-specific rabbit antibodies for 2 h and then washed 
twice for 10 min in blocking solution. The wash was followed 
by incubation with 200 nCi/ml of 1251-protein A for 1 h, a final 
wash as before, and autoradiography of the blot. 
3. RESULTS 
To test the ability of staurosporine to block a 
well-characterized protein kinase C-mediated 
event, we examined whether pretreatment with 
staurosporine for 2 h (to allow partitioning and en- 
zyme inhibition) could block the ability of TPA to 
decrease the number of high-affinity EGF receptor 
binding sites on the cell surface of MDA468 cells. 
Fig.1 shows that cells treated with TPA alone 
undergo adecrease in the binding of t25I-EGF. We 
have previously shown that this loss of binding 
results from a loss of high-affinity binding sites in 
these cells [7]. Beginning at 20 nM, staurosporine 
caused a dose-dependent i hibition of the effects 
of TPA on EGF binding, with an estimated ICs0 
value of approx. 30 nM. The highest dose of 
staurosporine routinely used (80 nM) blocked 87% 
of the effect of TPA. This inhibition occurred in 
the absence of any significant effect of 
staurosporine on EGF binding in control cells and 
in the absence of any observable cytotoxicity. 
Next, we investigated whether staurosporine 
could block the ability of EGF or TPA to cause an 
accumulation fEGF receptor and TGF-tr mRNA. 
The MDA468 cells were pretreated with 50 nM 
staurosporine, a concentration shown in the 
previous experiment to block the majority of 
TPA's effects on EGF binding. Fig.2 shows that in 
the absence of staurosporine, both EGF and TPA 
cause an accumulation f both EGF receptor and 
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Fig.l. Effect of staurosporine on the loss of EGF binding 
caused by TPA. MDA468 cells were treated with the indicated 
doses of stanrosporine in 0.5 ml of medium for 2 h, followed 
by treatment in the absence (m) or presence (A) of 100 ng/ml 
of TPA for a further 2 h. EGF binding was then measured. 
Non-specific binding of radioactive EGF as assessed by 
incubation in the presence of 2 x l0 -7 M unlabeled EGF was 
always below 0.5070 of the total counts added. Results represent 
means ± SE of triplicate wells. 
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Fig.2. Effect of staurosporine on the EGF- or TPA-induced 
accumulation of EGF receptor and TGF-a mRNA. MDA468 
cells were treated in the absence or presence of 50 nM 
staurosporine for 2 h, followed by incubations in the presence 
of either 10 -9 M EGF or 100 ng/ml TPA for a further 7 h. 
Cellular mRNA was probed with the TGF-a cDNA probe. 
Following autoradiography, the TGF-a probe was stripped 
from the membrane and the blot reprobed with the EGF 
receptor cDNA probe. 
TGF-a mRNA. In the presence of staurosporine, 
the effects of both EGF and TPA on EGF receptor 
and TGF-t~ mRNA are blocked. Staurosporine had 
no significant effect on either mRNA level in con- 
trol cells. Blots stripped and reprobed with the 
'housekeeping probe' hexosaminidase A con- 
firmed the absence of RNA gel loading artifacts 
and the relative specificity of the response (not 
shown). 
Because staurosporine could block the effects of 
EGF on EGF receptor and TGF-a mRNA ac- 
cumulation, we examined if this inhibitory effect 
could have been mediated through direct effects on 
the intrinsic tyrosine kinase activity of the EGF 
receptor. The MDA468 cells were pretreated for 
2 h with 50 nM staurosporine, followed by a 
15 min EGF treatment and measurement of the 
level of phosphotyrosine in immunoprecipitated 
EGF receptor. Fig.3 shows that both in the absence 
and presence of staurosporine, EGF stimulated 
Fig.3. Effect of staurosporine on EGF-stimulated tyrosine 
phosphorylation of the EGF receptor. MDA468 cells were 
treated in the absence (lanes 1,2) or presence (lanes 3,4) of 
50 nM stanrosporine for 2 h, followed by incubations in the 
absence (lanes 1,3) or presence (lanes 2,4) of 10 -9 M EGF for 
15 min. The EGF receptor was immunoprecipitated using an 
anti-EGF receptor antibody and immunoblotted with an anti- 
phosphotyrosine antibody. The quantity of bound antibody 
was determined with 1251-protein A followed by auto- 
radiography. 
phosphorylation of its receptor on tyrosine 
residues, with no obvious inhibitory effects 
displayed by staurosporine. 
4. DISCUSSION 
Staurosporine has been found to be a non- 
competitive inhibitor of protein kinase C with 
respect o phospholipid, Ca 2+, protein substrate 
(histone), ATP, diacylglycerol and phorbol esters 
[8]. The present study describes the ability of 
staurosporine to block certain cellular esponses in
the MDA468 breast cancer thought to be mediated 
by protein kinase C. The activation of protein 
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kinase C by TPA in the MDA468 cells, as in many 
others, results in the loss of high-affinity EGF- 
binding sites [19,20]. This effect of TPA is believed 
to be mediated through phosphorylation of the 
EGF receptor at Thr 654 by protein kinase C 
[21-23]. Pretreatment of the cells with 
staurosporine resulted in a dose-dependent 
diminution in the effect of TPA on EGF binding, 
implying that staurosporine i deed blocked TPA- 
stimulated EGF receptor transmodulation. 
Having established that staurosporine was 
capable of inhibiting a well characterized effect of 
protein kinase C activation in intact MDA468 
cells, we examined whether staurosporine could 
block the more distal effect of TPA on the expres- 
sion of the EGF receptor and TGF-a in these cells. 
In the absence of staurosporine, TPA stimulated 
the accumulation of both the EGF receptor and 
TGF-t~ mRNAs, while in its presence, this effect of 
TPA was completely blocked. EGF is also capable 
of stimulating EGF receptor [24,25] and TGF-~ 
mRNA [26[ accumulation i certain cells including 
the MDA468 cells. Staurosporine also blocked 
these EGF-stimulated effects. Previously, using 
TPA to downregulate protein kinase C in MDA468 
cells, we could block the stimulation of EGF recep- 
tor synthesis by TPA and EGF [7]. We hypothe- 
sized that the effect of EGF on the expression of 
the EGF receptor equires protein kinase C. The 
ability of staurosporine to block EGF-stimulated 
expression of the EGF receptor and TGF-~ sup- 
ports this hypothesis. 
While staurosporine inhibits protein kinase C 
activity, it may also inhibit the activity of other 
protein kinases [8,27] involved in signal transduc- 
tion, such as the intrinsic protein tyrosine kinase of 
the EGF receptor. The activity of this protein 
kinase is necessary for EGF action [28] and its in- 
hibition by staurosporine could explain the 
blockade of EGF-stimulated events. Autophos- 
phorylation of the EGF receptor is an early step in 
EGF signaling which can increase the affinity of 
the protein tyrosine kinase for other substrates 
[29]. Thus, EGF receptor autophosphorylation 
was examined to determine if staurosporine could 
block EGF action at this level. Pretreatment of in- 
tact cells with sufficient staurosporine to block 
TPA and EGF effects had no detectable effect on 
EGF-stimulated receptor autophosphorylation. 
Since autophosphorylation f the receptor was 
unaffected by staurosporine, it is improbable that 
staurosporine blocked distal effects of EGF by 
blocking the EGF receptor protein tyrosine kinase. 
A more plausible explanation, combined with our 
earlier results in protein kinase C-depleted cells, 
would be that EGF requires activatable protein 
kinase C for its action on the expression of the 
EGF receptor and TGF-a. In concert with this no- 
tion, EGF has been shown to stimulate the ac- 
cumulation of inositol trisphosphate (IP3) in 
MDA468 cells [30] suggesting that EGF stimula- 
tion might involve second messenger generation 
via the phosphatidylinositol cycle. Furthermore, 
evidence that the EGF receptor may phosphorylate 
phospholipase C and activate this enzyme [31] may 
explain the mechanism by which protein kinase C 
is involved in EGF action. The ability of stauro- 
sporine to block responses to both EGF and TPA 
suggests that these two agents ignal through com- 
mon pathways. 
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